Skip to main content
Publications
Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J , Zhou X , Gnanasakthy A , Taylor K, Yusuf A, Maher I, Jamotte A, Kang Y-K. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer . ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095
Hamadani M, Spira AI, Zhou X , Liao L, Chen L, Radford J, Ai WZ, Solh MM, Ardeshna KM, Hess BT, Caimi PF, Stathis A, Carlo Stella C, Alderuccio JP, Kahl BS, Wang Y, Qin YG, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial . Blood Adv. 2024 Jan;9(1):93-8. doi: 10.1182/bloodadvances.2023010636
Anthony MS , Zhou X , Schoendorf J, Reed SD, Getahun D, Armstrong MA, Gatz J, Peipert JF, Raine-Bennett T, Fassett MJ, Saltus CW , Ritchey ME, Ichikawa L, Shi JM, Alabaster A, Wahdan Y, Wang J , Xie F, Merchant M, Hunter S, Chiu VY, Postlethwaite D, Rothman KJ , Im TM, Chillemi G, Takhar HS, Asiimwe A, Pisa F. Demographic, reproductive, and medical risk factors for intrauterine device explusion . Obstet Gynecol. 2022 Nov 3;140(6):1017-30. doi: 10.1097/AOG.0000000000005000
Spira A, Zhou X , Liao L, Yu E, Chen L, Lau A, Wang Y, Gnanasakthy A , Radford J, Hamadani M. Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2) . Poster presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022); September 28, 2022. Houston, TX.
Gatz JL, Armstrong MA, Postlethwaite D, Raine-Bennett T, Chillemi G, Alabaster A, Merchant M, Reed SD, Ichikawa L, Getahun D, Fassett MJ, Shi JM, Xie F, Chiu VY, Im TM, Takhar HS, Wang J , Saltus CW , Ritchey ME, Asiimwe A, Pisa F, Schoendorf J, Wahdan Y, Zhou X , Hunter S, Anthony MS , Peipert JF. Association between intrauterine device type and risk of perforation and device expulsion: results from the APEX-IUD study . Am J Obstet Gynecol. 2022 Jul 1;227(1):57.e1-57.. doi: 10.1016/j.ajog.2022.03.062
Spira A, Liao L, Zhou X , Gnanasakthy A , Chen L, Ungar D, Yu E, Kilavuz T, Radford J, Hamadani M. Health-related quality of life and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large B-cell lymphoma treated in a phase 2 clinical trial (LOTIS 2) . Poster presented at the 2022 EHA Congress; June 9, 2022. Vienna, Austria.
Reed SD, Zhou X , Ichikawa L, Gatz JL, Peipert JF, Armstrong MA, Raine-Bennett T, Getahun D, Fassett MJ, Postlethwaite DA, Shi JM, Asiimwe A, Pisa F, Schoendorf J, Saltus CW , Anthony MS , APEX-IUD study team. Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study . Lancet. 2022 Jun 4;399(10341):2103-12. doi: 10.1016/S0140-6736(22)00015-0
Getahun D, Fassett MJ, Gatz J, Armstrong MA, Peipert JF, Raine-Bennett T, Reed SD, Zhou X , Schoendorf J, Postlethwaite D, Shi JM, Saltus CW , Wang J , Xie F, Chiu VY, Merchant M, Alabaster A, Ichikawa LE, Hunter S, Im TM, Takhar HS, Ritchey ME, Chillemi G, Pisa F, Asiimwe A, Anthony MS . Association between menorrhagia and risk of intrauterine device-related uterine perforation and device expulsion: results from the APEX-IUD Study . Am J Obstet Gynecol. 2022 Jun;399(10341):2103-12. doi: 10.1016/j.ajog.2022.03.025
Spira A, Liao L, Zhou X , Sherif B , Chen L, Ungar D, Yu E, Radford J, Hamadani M. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in older versus younger patients with relapsed/refractory diffuse large b-cell lymphoma treated in a phase 2 clinical trial (LOTIS-2) . Poster presented at the National Comprehensive Cancer Network (NCCN) 2022 Virtual Annual Conference; March 31, 2022.
Spira A, Zhou X , Chen L, Gnanasakthy A , Wang L, Ungar D, Curiel R, Liao L, Radford J, Kahl B. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in patients with relapsed or refractory diffuse large b-cell lymphoma . Clin Lymphoma Myeloma Leuk. 2022 Mar;22(3):158-68. doi: 10.1016/j.clml.2021.09.001
Armstrong MA, Raine-Bennett T, Reed SD, Gatz J, Getahun D, Schoendorf J, Postlethwaite D, Fassett MJ, Peipert JF, Saltus CW , Merchant M, Alabaster A, Zhou X , Ichikawa L, Shi JM, Chiu VY, Xie F, Hunter S, Wang J , Ritchey ME, Chillemi G, Im TM, Takhar HS, Pisa F, Asiimwe A, Anthony MS . Association of the timing of postpartum intrauterine device insertion and breastfeeding with risks of intrauterine device expulsion . JAMA Netw Open. 2022 Feb 28;5(2):e2148474. doi: 10.1001/jamanetworkopen.2021.48474
Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X , Park J, Ridolfi A, Lorenzo I, Andre F. Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2–negative advanced breast cancer from SOLAR-1 . J Clin Oncol. 2021 Jun 20;39(18):2005-15. doi: 10.1200/JCO.20.01139
Anthony MS , Reed SD, Armstrong MA, Getahun D, Gatz JL, Saltus CW , Zhou X , Schoendorf J, Postlethwaite DA, Raine-Bennett T, Fassett MJ, Peipert JF, Ritchey ME, Ichikawa LE, Lynen R, Alabaster AL, Merchant M, Chiu VY, Shi JM, Xie F, Hui SL, Wang J , Hunter S, Bartsch J , Frenz AK, Chillemi G, Im TM, Takhar HS, Asiimwe A. Design of the association of uterine perforation and expulsion of intrauterine device study: a multisite retrospective cohort study . Am J Obstet Gynecol. 2021 Jun;224(6):599.e1. doi: 10.1016/j.ajog.2021.01.003.
Spira AI, Chen L, Zhou X , Gnanasakthy A , Wang L, Ungar D, Curiel R, Radford JA, Kahl BS. Symptoms, health-related quality of life, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large b cell lymphoma . Blood. 2020 Nov 5;136(Suppl 1):3-4. doi: 10.1182/blood-2020-139571
Reed S, Getahun D, Gatz J, Armstrong M, Raine-Bennett T, Zhou X , Fassett M, Peipert J, Saltus CW , Im T, Alabaster A, Hunter S, Takhar H, Chillemi G, Xie F, Wang J , Chiu V, Frenz A, Shi J, Lynen R, Asiimwe A, Anthony MS . Postpartum timing of IUD insertion is associated with risk of uterine perforation: results from APEX IUD . Poster presented at the Society of Family Planning Virtual 2020 Annual Meeting; October 9, 2020. [abstract] Contraception. 2020 Oct; 102(4):302. doi: 10.1016/j.contraception.2020.07.099
Raine-Bennett TR, Gatz JL, Reed SD, Armstrong MA, Getahun D, Zhou X , Merchant M, Takhar HS, Ichikawa LE, Peipert JF, Saltus CW , Fassett MJ, Chillemi GA, Im TM, Lynen R, Shi JM, Wang J , Xie F, Hunter S, Chiu VY, Asiimwe A, Anthony MS . Postpartum timing of IUD insertion is associated with risk of IUD expulsion: results from APEX IUD . Poster presented at the Society of Family Planning Virtual 2020 Annual Meeting; October 9, 2020. [abstract] Contraception. 2020 Oct; 102(4):295-6.
Reed SD, Armstrong MA, Getahun D, Gatz JL, Raine-Bennett TR, Alabaster AL, Ichikawa L, Saltus CW , Xie F, Zhou X , Fassett MJ, Peipert JF, Merchant M, Chiu VY, Hunter S, Schoendorf J, Shi JM, Chillemi GA, Im TM, Takhar HS, Asiimwe A, Anthony MS . Risk of uterine perforation and expulsion associated with breastfeeding among postpartum women with an intrauterine device insertion: results from APEX IUD . Poster presented at the Society of Family Planning Virtual 2020 Annual Meeting; October 9, 2020. [abstract] Contraception. 2020 Oct; 102(4):297.
Reed SD, Saltus CW , Getahun D, Schoendorf J, Armstrong MA, Peipert JF, Raine-Bennett TR, Ritchey ME, Ichikawa LE, Zhou X , Fassett MJ, Alabaster A, Xie F, Merchant M, Chiu VY, Shi JM, Frenz A-K, Im TM, Takhar HS, Lynen R, Asiimwe A, Anthony MS . Menorrhagia and risk of intrauterine device (IUD) expulsion and uterine perforation: results from the APEX IUD study . Presented at the Virtual 76th Scientific Congress of the American Society for Reproductive Medicine (ASRM); October 17, 2020. [abstract] Fertil Steril. 2020 Sep 1; 114(3 Suppl):e12. doi: 10.1016/j.fertnstert.2020.08.059
Mease P, Gladman D, Davenport E , Zhou X , Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naïve subjects with active psoriatic arthritis . Poster presented at the 37th Scandinavian Congress of Rheumatology; September 5, 2018. Helsinki, Finland. [abstract] Scand J Rheumatol. 2018 Sep 5; 47(Suppl 129):34-5. Previously presented at the 2017 ACR/ARHP Annual Meeting.
Mease PJ, Gladman DD, Davenport EK , Zhou X , Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomised, controlled study in biologic-naÏve subjects with active psoriatic arthritis . Poster presented at the EULAR 2018 Annual European Congress of Rheumatology; June 13, 2018. Amsterdam, The Netherlands. [abstract] Ann Rheum Dis. 2018 Jun 12; 77(Suppl 2):A1598. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.1136/annrheumdis-2018-eular.3139
Mease PJ, Gladman DD, Davenport EK , Zhou X , Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis . Poster presented at the 5th World Psoriasis & Psoriatic Arthritis Conference 2018; June 27, 2018. Stockholm, Sweden. [abstract] Acta Derm Venereol. 2018 Jun; 98(Suppl 219):14. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.2340/00015555-2978
Mease PJ, Gladman DD, Davenport EK , Zhou X , Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis . Poster presented at the 2017 ACR/ARHP Annual Meeting; November 5, 2017. San Diego, CA.
Nabhan C, Zhou X , Day BM, Dawson K, Zelenetz AD, Friedberg JW, Cerhan JR, Link BK, Flowers CR. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States . Am J Hematol. 2016 Aug;91(8):770-5. doi: 10.1002/ajh.24401